Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;62(2):112-9.
doi: 10.1002/iub.293.

Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications

Affiliations
Review

Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications

Hui Zheng et al. IUBMB Life. 2010 Feb.

Abstract

Agonist-selective signaling or ligand-biased signaling of G protein-coupled receptor (GPCR) has become the focus of an increasing number of laboratories. The principle of this concept is that agonist possesses different abilities to activate different signaling pathways. Current review summarizes the observations of agonist-selective signaling of various GPCRs, indicating the significance of agonist-selective signaling in biological processes. In addition, current review also provides an overview on how agonist-selective signaling is initiated. Especially, the relationship between GPCR-G protein interaction and GPCR-beta-arrestin interaction is discussed in depth.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematic representation of agonist-selective signaling
Agonist I and II exhibit differential efficacies in pathway A and B. The “Full Agonist” and “Neutral Antagonist” were used to indicate the different “intrinsic efficacies” of these agonists on the two pathways. Also, they can be “Partial Agonist” or “Inverse Agonist”.
Figure 2
Figure 2. Schematic diagram of the competition between G protein and β-arrestin
“G” and “Phos” were used to represent G protein and phosphorylation of GPCR, respectively.

Similar articles

Cited by

References

    1. Ariens EJ. Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther. 1954;99:32–49. - PubMed
    1. Furchgott R. The use of haloalkylamines in the differentiation of receptors and in the determination of dissciationof receptor-agonist complexes. Adv Drug Res. 1966;3:21–55. Harper NJ and Simmonds AB eds.
    1. Kenakin T. Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci. 1995;16:188–92. - PubMed
    1. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci. 1995;16:256–8. - PubMed
    1. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320:1–13. - PubMed

Publication types

MeSH terms

LinkOut - more resources